This proposal seeks to continue a Clinical Hematology Career Development Program in benign hematology and transfusion medicine at the Johns Hopkins Medical Institutions (JHMI). The next generation of clinical researchers in benign hematology and transfusion medicine will need to include individuals with the skills, attitudes, early research training and experience to capitalize on rapidly developing progress in these disciplines. In developing this program, we will use established research infrastructure, including free-standing Divisions of Hematology in Pediatrics, Internal Medicine and Transfusion Medicine that are dedicated to the care and study of benign hematologic disorders, as well as our Graduate Training Program in Clinical Investigation (GTPCI) at the Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health.
Our specific aims are: a) To continue to identify, recruit, train and develop creative and successful clinical investigators, with the capability to interact with, participate in, and lead multidisciplinary teams involved in clinical research, address complex problems and become national leaders in pediatric, adolescent and adult benign hematology and transfusion medicine;b) To provide trainees with the requisite skills, knowledge, attitude and experience for successful academic careers in clinical research in these areas. This training will include exposure to national and international leaders and curriculum in the multiple disciplines necessary for successful clinical research, including benign hematology, transfusion medicine, clinical trials design, epidemiology, statistics, research ethics and human subjects protection;c) To provide a rich mentoring environment. We will integrate multiple research resources and investigators available at the JHMI to provide optimal exposure of trainees to research experiences and training. We will continue to focus our efforts in six areas where we feel there is particular strength within our institution: bone marrow failure and stem cell biology, sickle cel disease (SCD), myeloproliferative disorders, transfusion medicine, outcomes research and genetics. We will work with several established investigators and mentors to develop a structured curriculum in benign hematology and strong mentored research experiences for trainees. Careful and extensive mentoring will be the cornerstone of these efforts, with exposure to cutting edge research experiences. Through this program, we ultimately aim to provide a cadre of clinical researchers, who will become creative, independent investigators, care for patients and assume leadership roles in benign clinical hematology.

Public Health Relevance

Many diseases of the blood (hematologic) are serious, but rare, and need to be better studied and treated. Most physicians specializing in hematology train in both oncology (cancer) and hematology;as reimbursement for the treatment of cancer is better than for hematologic conditions, the number of hematologists (blood doctors) and transfusion medicine specialists seems to be decreasing. This project aims to assure that there will be enough well trained hematologists in the future with the skills and knowledge necessary to address complex problems in blood diseases and transfusion medicine and care for the patients with these disorders.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (F1))
Program Officer
Werner, Ellen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Braunstein, Evan M; Moliterno, Alison R (2014) Back to biology: new insights on inheritance in myeloproliferative disorders. Curr Hematol Malig Rep 9:311-8
Naik, Rakhi P; Derebail, Vimal K; Grams, Morgan E et al. (2014) Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 312:2115-25
Lance, Eboni I; Casella, James F; Everett, Allen D et al. (2014) Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease. Proteomics Clin Appl 8:813-27
Naik, R P; Streiff, M B; Haywood Jr, C et al. (2014) Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost 12:2010-6
Naik, Rakhi P; Streiff, Michael B; Lanzkron, Sophie (2013) Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 35:352-8
Naik, Rakhi P; Streiff, Michael B; Lanzkron, Sophie (2013) The reply. Am J Med 126:e15
DeZern, Amy E; Dorr, Donna; Brodsky, Robert A (2013) Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol 90:16-24
Savage, William J; Reddoch, Shirley; Wolfe, Jaime et al. (2013) Partial manual exchange reduces iron accumulation during chronic red cell transfusions for sickle cell disease. J Pediatr Hematol Oncol 35:434-6
Savage, William J; Savage, Jessica H; Tobian, Aaron A R et al. (2012) Allergic agonists in apheresis platelet products are associated with allergic transfusion reactions. Transfusion 52:575-81
Stein, Brady L; Williams, Donna M; Rogers, Ophelia et al. (2011) Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol 39:95-101

Showing the most recent 10 out of 24 publications